Business
Hemostemix Announces Annual Special Meeting Results
Calgary, Alberta--(Newsfile Corp. - May 7, 2020) -  Hemostemix Inc. (TSXV: HEM) (OTC: HMT...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Annual Special Meeting ResultsCalgary, Alberta--(Newsfile Corp. - May 7, 2020) -  Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (\"Hemostemix\" or the \"Company\") announces the Company completed its Annual Special Meeting of Shareholders on May 6, 2020. All motions put forward by management were approved by Shareholders, including the consolidation of the common shares on a one (1) new share for each 20 shares issued. The vote results are detailed in the attached table.Vote DetailsResolutionVote typeVotedVoted (%)O/S (%)Number of DirectorsFor233,236,23999.9940.68Against30,9300.010.01Peter Lacey, IndependentFor232,834,44999.8140.61Withheld432,7200.190.08Dr. Ronnie Hershman, IndependentFor212,015,29090.8936.98Withheld21,251,8799.113.71Loran Swanberg, IndependentFor232,846,44899.8240.62Withheld420,7210.180.07Thomas SmeenkFor201,623,57786.4335.17Withheld31,643,59213.575.52Appointment of AuditorsFor233,620,93899.9940.76Withheld20,0000.010Share ConsolidationFor232,199,82699.3840.51Against1,441,1110.620.25Stock Option PlanFor230,051,86298.6240.13Against3,215,3071.380.56 ABOUT HEMOSTEMIXHemostemix is a publicly traded autologous stem cell therapy company and a winner of the World Economic Forum Technology Pioneer Award. The Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled \"Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup\" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.The Company owns 91 patents across five patent families, including Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, pleas...